These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 20692869

  • 1. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage.
    Pletz MW, van der Linden M, von Baum H, Duesberg CB, Klugman KP, Welte T, CAPNETZ study group.
    Int J Med Microbiol; 2011 Jan; 301(1):53-7. PubMed ID: 20692869
    [Abstract] [Full Text] [Related]

  • 2. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006.
    Adam HJ, Hoban DJ, Gin AS, Zhanel GG.
    Int J Antimicrob Agents; 2009 Jul; 34(1):82-5. PubMed ID: 19342204
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN, Fritsche TR, Sader HS.
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [Abstract] [Full Text] [Related]

  • 4. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 5. TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents.
    Morrissey I, Colclough A, Northwood J.
    Int J Antimicrob Agents; 2007 Oct; 30(4):345-51. PubMed ID: 17643269
    [Abstract] [Full Text] [Related]

  • 6. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
    Deshpande LM, Sader HS, Debbia E, Nicoletti G, Fadda G, Jones RN, SENTRY Antimicrobial Surveillance Program (2001-2004).
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: analysis using current breakpoints and fluoroquinolone pharmacodynamics.
    Feldman C, Brink AJ, von Gottberg A, Wolter N, de Gouveia L, Perovic O, Klugman KP.
    Int J Antimicrob Agents; 2010 Jul; 36(1):95-7. PubMed ID: 20378315
    [No Abstract] [Full Text] [Related]

  • 8. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [Abstract] [Full Text] [Related]

  • 9. High prevalence of multidrug-resistant Pneumococcal molecular epidemiology network clones among Streptococcus pneumoniae isolates from adult patients with community-acquired pneumonia in Japan.
    Imai S, Ito Y, Ishida T, Hirai T, Ito I, Maekawa K, Takakura S, Iinuma Y, Ichiyama S, Mishima M, Kansai Community Acquired Pneumococcal Pneumonia Study Group.
    Clin Microbiol Infect; 2009 Nov; 15(11):1039-45. PubMed ID: 19694764
    [Abstract] [Full Text] [Related]

  • 10. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 11. Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST Surveillance isolates since 2001.
    Davies TA, Yee YC, Goldschmidt R, Sahm DF, Evangelista AT.
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):39-45. PubMed ID: 18931470
    [Abstract] [Full Text] [Related]

  • 12. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN, Adam HJ, Siemens CG, Hoban CJ, Hoban DJ, Zhanel GG.
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [Abstract] [Full Text] [Related]

  • 13. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ, Toleman MA, Walsh TR, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):119-27. PubMed ID: 16530373
    [Abstract] [Full Text] [Related]

  • 14. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England.
    Johnson AP, Sheppard CL, Harnett SJ, Birtles A, Harrison TG, Brenwald NP, Gill MJ, Walker RA, Livermore DM, George RC.
    J Antimicrob Chemother; 2003 Dec; 52(6):953-60. PubMed ID: 14585858
    [Abstract] [Full Text] [Related]

  • 15. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C.
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [Abstract] [Full Text] [Related]

  • 16. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
    Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL.
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
    [Abstract] [Full Text] [Related]

  • 17. Quinolone resistance among pneumococci: therapeutic and diagnostic implications.
    Low DE.
    Clin Infect Dis; 2004 May 15; 38 Suppl 4():S357-62. PubMed ID: 15127370
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan.
    Ishida T, Maniwa K, Kagioka H, Hirabayashi M, Onaru K, Tomioka H, Hayashi M, Tomii K, Gohma I, Ito Y, Hirai T, Ito I, Mishima M.
    Respirology; 2008 Mar 15; 13(2):240-6. PubMed ID: 18339022
    [Abstract] [Full Text] [Related]

  • 19. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A, Schubert S.
    Int J Antimicrob Agents; 2010 Sep 15; 36(3):216-21. PubMed ID: 20630710
    [Abstract] [Full Text] [Related]

  • 20. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004).
    Draghi DC, Jones ME, Sahm DF, Tillotson GS.
    Int J Antimicrob Agents; 2006 Dec 15; 28(6):525-31. PubMed ID: 17101260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.